Class Action Lawsuit Update for Sage Therapeutics
Pomerantz LLP has announced that a class action lawsuit has been initiated against Sage Therapeutics, Inc. (NASDAQ: SAGE) and its certain officers. This legal action arises from an alleged violation of federal securities laws during a particular period when numerous stakeholders acquired Sage's securities.
Details of the Class Action Lawsuit
The class action, lodged in the U.S. District Court for the Southern District, encompasses all entities besides the defendants that purchased shares of Sage stock between specified dates. Those who acquired Sage's securities within this timeframe are invited to step forward and potentially appoint themselves as Lead Plaintiffs.
Lead Plaintiff Opportunity
Should you have purchased Sage securities during this period, you have until the end of October to express your interest in being appointed as a Lead Plaintiff. Engaging in this legal action could provide a pathway for recouping some losses caused by the alleged misleading assertions made by the company regarding its business operations.
Sage's Product Pipeline and Developments
Sage Therapeutics is immersed in developing innovative medications aimed at enhancing brain health. Key products include zuranolone (SAGE-217/BIIB125), targeted at treating postpartum depression and major depressive disorder, created in partnership with Biogen Inc. Moreover, Sage is working on SAGE-718, a treatment for cognitive challenges linked to Parkinson's Disease, and SAGE-324, which aims to address essential tremor conditions.
Regulatory Submissions and Outcomes
As part of its regulatory efforts, Sage began submitting a New Drug Application for zuranolone intended for major depressive disorder treatment. However, instead of separate filings for its two indications, the company consolidated its submission to expedite the regulatory process.
Allegations Against the Company
Throughout the defined class period, Sage allegedly provided a series of misleading statements, causing investors to receive a distorted view of the company’s effectiveness and prospects. Issues were raised regarding the efficacy of zuranolone in treating key mental health disorders, implying significant discrepancies between the company’s earlier assertions and the reality of the drug's effectiveness.
Impact of Recent Developments on Stock Performance
The market response to disclosures about the company's drug approvals and sales has led to considerable volatility in Sage's stock price. Following significant announcements regarding the effectiveness of its treatments, particularly for zuranolone and SAGE-718, the stock witnessed steep declines, reflecting investor concerns over the viability of these therapies moving forward.
Future Development Plans
Despite setbacks, Sage continues to assess its drug candidates, including SAGE-718 and SAGE-324, for their ongoing development. However, recent findings about their efficacies have led the company to reconsider its approach, potentially halting the further pursuit of specific treatments based on clinical results.
Pomerantz LLP's Role and Commitment
Pomerantz LLP stands as an advocate for those adversely affected by corporate misconduct. With a historic legacy in class action litigation, they ensure that shareholders can pursue accountability from companies over misleading information affecting stock values.
Frequently Asked Questions
What is the class action lawsuit against Sage Therapeutics about?
The lawsuit is regarding alleged violations of securities laws related to misleading statements made by Sage about their business operations and product effectiveness.
When is the deadline to become a Lead Plaintiff?
Shareholders who acquired Sage securities have until October 28, 2024, to request to be appointed as Lead Plaintiff in the class action.
Which products are being developed by Sage Therapeutics?
Sage is developing several products, including zuranolone for depression, SAGE-718 for cognitive impairment, and SAGE-324 for essential tremor.
What caused Sage's stock price to decline significantly?
Sage's stock fell sharply following disclosures from the FDA regarding the approval status of zuranolone and the efficacy results of their clinical trials for other products.
What is the role of Pomerantz LLP?
Pomerantz LLP represents shareholders affected by corporate wrongdoing, specializing in securities litigation to recover damages for investors.
